IGC Pharma, Inc. (NYSE: IGC) announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its application covering IGC510, a novel treatment method using THC and/or CBD microdoses to address stammering, stuttering, and Tourette’s syndrome.

The patent allowance adds to IGC’s expanding intellectual property portfolio, which already spans Alzheimer’s, pain, and eating disorder therapies leveraging low-dose cannabinoids. The company’s therapeutic strategy combines small amounts of THC with atypical antipsychotics to enhance treatment efficacy while minimizing the side effects often associated with higher doses.

IGC intends to advance IGC510 toward clinical formulations similar to its lead program IGC-AD1, a cannabinoid-based therapy currently in Phase 2 CALMA trials for agitation in Alzheimer’s dementia.

IGC currently has more than 30 active patent filings and 12 granted patents and continues to pursue a pipeline of AI-accelerated therapies addressing neurodegenerative and metabolic disorders.

The post IGC Pharma Secures U.S. Patent Allowance for THC-Based Microdose Therapy appeared first on PRISM MarketView.